Table 1 Demographic and clinical characteristics of study population
Characteristics | RA patients (n = 50) | Control subjects (n = 25) | P |
|---|---|---|---|
Age, years | 60.9 ± 8.3 | 59.6 ± 5.3 | 0.42 |
Gender (female), % | 74.0% | 72.0% | 0.85 |
Body mass index, kg/m2 | 27.0 ± 6.0 | 28.9 ± 8.3 | 0.32 |
Current smokers, % | 16.0% | 16.0% | 1.00 |
Diabetes, % | 6.0% | 12.0% | 0.36 |
Family history of cardiovascular disease, % | 18.0% | 20.0% | 0.83 |
Hypertension, % | 64.0% | 48.0% | 0.50 |
Current use of antihypertensive therapy, % | 44.0% | 36.0% | 0.50 |
Systolic blood pressure, mmHg | 126.2 ± 17.0 | 129.3 ± 18.4 | 0.45 |
Diastolic blood pressure, mmHg | 81.0 ± 12.3 | 82.6 ± 11.6 | 0.59 |
Hypercholesterolemia, % | 36.0% | 48.0% | 0.74 |
Current use of statins, % | 24.0% | 16.0% | 0.32 |
Current use of fibrates, % | 2.0% | 16.0% | 0.02 |
FRS, % | 11.4% | 13.8% | 0.36 |
RF and/or CCP antibodies, % | 86.0% | - | |
Erosive arthritis, % | 54.0% | - | |
Duration of disease (years) | 12.2 ± 8.5 | - | |
HAQ | 0.8 ± 0.7 | - | |
DAS28-hs-CRP | 2.5 ± 0.9 | - | |
DAS28-hs-CRP ≤3.2, % | 80.0% | - | |
Current methotrexate users, % | 90.0% | - | |
Current anti-TNFα users, % | 58.0% | - | |
Current NSAIDs users, % | 30.0% | - | |
Current corticosteroid users, % | 26.0% | - |